Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06175390 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Study acronym: SKYLINE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 130 to confirmed 81
    • Site details revised at 2 of 2 sites
    v7
  2. Enrollment target: 160 to 130
    • Eligibility criteria expanded, about 9 words
    v6
  3. Start date changed from estimate of Mar 2024 to Mar 27, 2024
    • Site contacts updated at 2 of 2 sites
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 15, 2024 to Mar 2024
    • Site details revised at 2 of 2 sites
    v4
  5. Start date: Jan 15, 2024 to Feb 15, 2024
    • Primary completion date: Jul 15, 2026 to Aug 15, 2026
    • Study completion date: Jan 15, 2029 to Feb 15, 2029
    v3
  6. Eligibility criteria revised
    • Secondary endpoints revised (9)
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer (TNBC) patients and cohort B in late in metastatic TNBC patients) designed to evaluate the efficacy of atezolizumab, tiragolumab and chemotherapy.
Trial Details
NCT Number NCT06175390
Lead Sponsor Institut Curie
Collaborators: Hoffmann-La Roche
Conditions
(from sponsor)		 Triple Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 81 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov